Evidence map›Paper›PMID 29249827›Full record

ArticleTranslational psychiatry2017

Schizophrenia-risk and urban birth are associated with proteomic changes in neonatal dried blood spots.

Jason D Cooper, Sureyya Ozcan, Renee M Gardner, Nitin Rustogi, Susanne Wicks, Geertje F van Rees, F Markus Leweke, Christina Dalman, Håkan Karlsson, Sabine Bahn

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational psychiatry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
1.0field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Jason D CooperDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Sureyya OzcanDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Renee M GardnerDepartment of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.
Nitin RustogiDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
Susanne WicksDepartment of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.
Geertje F van ReesDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK.
F Markus LewekeBrain and Mind Centre, University of Sydney, Sydney, Australia.
Christina DalmanDepartment of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.
Håkan KarlssonDepartment of Public Health Sciences, Karolinska Institutet, Stockholm, Sweden.
Sabine BahnDepartment of Chemical Engineering and Biotechnology, University of Cambridge, Cambridge, UK. sb209@cam.ac.uk.
University of Cambridge · GBKarolinska Institutet · SEStockholm County Council · SEUniversity of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the present study, we tested whether there were proteomic differences in blood between schizophrenia patients after the initial onset of the disorder and controls; and whether those differences were also present at birth among neonates who later developed schizophrenia compared to those without a psychiatric admission. We used multiple reaction monitoring mass spectrometry to quantify 77 proteins (147 peptides) in serum samples from 60 first-onset drug-naive schizophrenia patients and 77 controls, and 96 proteins (152 peptides) in 892 newborn blood-spot (NBS) samples collected between 1975 and 1985. Both serum and NBS studies showed significant alterations in protein levels. Serum results revealed that Haptoglobin and Plasma protease C1 inhibitor were significantly upregulated in first-onset schizophrenia patients (corrected P < 0.05). Alpha-2-antiplasmin, Complement C4-A and Antithrombin-III were increased in first-onset schizophrenia patients (uncorrected P-values 0.041, 0.036 and 0.013, respectively) and also increased in newborn babies who later develop schizophrenia (P-values 0.0058, 0.013 and 0.044, respectively). We also tested whether protein abundance at birth was associated with exposure to an urban environment during pregnancy and found highly significant proteomic differences at birth between urban and rural environments. The prediction model for urbanicity had excellent predictive performance in both discovery (area under the receiver operating characteristic curve (AUC) = 0.90) and validation (AUC = 0.89) sample sets. We hope that future biomarker studies based on stored NBS samples will identify prognostic disease indicators and targets for preventive measures for neurodevelopmental conditions, particularly those with onset during early childhood, such as autism spectrum disorder.

Indexed as

ProteomicsAdultBiomarkersComplement C1 Inhibitor ProteinFemaleHaptoglobinsHumansInfant, NewbornMaleMass SpectrometryNeonatal ScreeningRisk FactorsSchizophreniaUrban PopulationYoung AdultBiomarkersComplement C1 Inhibitor ProteinHaptoglobins

Identifiers

PMID29249827
PMCPMC5802534
OpenAlexW2772300842

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.